



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 11, 2012 6:00 – 8:30 p.m.

PLEASE NOTE NEW START TIMES – PUBLIC SESSION STARTS AT 6:30 PM

- 1. Executive Session** **6:00 - 6:30**
 - Discussion on Medicaid OBRA '90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:45**
 - Updates

- 4. Medical Director Update** **6:45 - 6:45**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:45 - 7:00**
 - Atypical Antipsychotic Medications – Pediatric Use

- 6. RetroDUR/DUR** **7:00 – 7:30**
 - Hepatitis C Protease Inhibitors
 - Narcotic Analgesics – continued use of short acting with no long acting
 - New Topics – Board Discussion of Possible Topics

- 7. Clinical Update: Drug Reviews** **7:30 – 8:00**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Combivent[®] (ipratropium bromide/albuterol) Respimat
 - QNASL[®] (beclomethasone dipropionate HFA) Nasal Spray
 - Subsys[®] (fentanyl) Sublingual Spray

 - Full New Drug Reviews**
 - Arcapta[®] (indacaterol) Neohaler
 - Dymista[®] (azelastine/fluticasone) Nasal Spray
 - Korlym[®] (mifepristone) Oral Tablet
 - Zetonna[®] (ciclesonide) Nasal Aerosol

- 8. Therapeutic Drug Classes – Periodic Review** **8:00 – 8:10**
(Public comment prior to Board action)
Class review documents available on DVHA web site 12/11/2012 @ 12 Noon
- Restless Leg Syndrome Medications (including Neupro[®])
- 9. New Managed Therapeutic Drug Classes** **8:10 – 8:10**
(Public comment prior to Board action)
- None
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:10 – 8:20**
(Public comment prior to Board action)
- Diabetic Testing Supplies
 - Pancreatic Enzymes
- 11. General Announcements** **8:20– 8:30**
Selected FDA Safety Alerts
- Fungal Meningitis Outbreak Originating from Compounding Pharmacy
 - Pradaxa[®]: Update on Safety Review
 - Pramipexole: Possible Risk of Heart Failure
- 12. Adjourn** **8:30**